We also characterized the role of the PKCα/AKT pathway in XIAP downregulation in AsPC-1 cells, which suggests that the inhibition of this pathway is an attractive target in pancreatic cancer therapy (Figure 5). This evidence concerns the gene PRKCA and familial pancreatic carcinoma.